X
[{"orgOrder":0,"company":"CDR Life","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"$494.0 million","upfrontCash":"Undisclosed","newsHeadline":"Boehringer Ingelheim Collaborates with CDR-Life to Develop Antibody Fragment-based Therapeutics for Geographic Atrophy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"CDR Life"},{"orgOrder":0,"company":"Arctos Medical","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novartis Acquires Arctos Medical, Expanding Optogenetics Portfolio to Bring Gene Therapies to Patients with Severe Vision Loss","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Arctos Medical"},{"orgOrder":0,"company":"CDR Life","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"$487.7 million","upfrontCash":"Undisclosed","newsHeadline":"CDR-Life Announces Second Milestone Achievement with Boehringer Ingelheim in Developing Antibody Fragment-based Therapeutics for Geographic Atrophy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"CDR Life"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
Details:
Under the collaboration, the partners will advance CDR-Life’s preclinical antibody fragment-based therapeutic including CDR202, targeting a key pathway in geographic atrophy (GA).
Lead Product(s):
CDR202
Therapeutic Area: Ophthalmology
Product Name: CDR202
Highest Development Status: Preclinical
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Boehringer Ingelheim GmbH
Deal Size: $487.7 million
Upfront Cash: Undisclosed
Deal Type: Collaboration
August 02, 2023
Details:
The acquisition underscores the Novartis commitment to finding treatments for patients with vision loss and the potential of Optogenetics-based AAV gene therapy as the basis of successful therapeutics.
Lead Product(s):
Optogenetics-based AAV Gene Therapy
Therapeutic Area: Ophthalmology
Product Name: Undisclosed
Highest Development Status: Preclinical
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Novartis Pharmaceuticals Corporation
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Acquisition
September 21, 2021
Details:
Together, with Boehringer Ingelheim’s expertise in the therapeutic development of biologics and CDR-Life’s strong know-how in antibody engineering, the two companies will progress CDR-Life’s preclinical candidate, with the aim to preserve sight for patients with GA.
Lead Product(s):
Antibody fragment-based therapeutics
Therapeutic Area: Ophthalmology
Product Name: Undisclosed
Highest Development Status: Preclinical
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Boehringer Ingelheim GmbH
Deal Size: $494.0 million
Upfront Cash: Undisclosed
Deal Type: Licensing Agreement
May 13, 2020